Author

J. Philip

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Animal Behavior & Cognition· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:Arabidopsis· 1 Assay:behavioral assay· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:clustering· 1

Frequent Co-Authors

A. E. Ikui· 1 shared A. Iavarone· 1 shared A. J. Dannenberg· 1 shared A. Kentsis· 1 shared A. Lasorella· 1 shared A. S. Gamis· 1 shared A. Silva· 1 shared A.-K. Emde· 1 shared

Activity by Year

2018-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

A. E. Ikui

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Among-individual variation of risk-taking behaviour in group and solitary context is uncorrelated but independently repeatable in a juvenile Arctic charr (Salvelinus alpinus) aquaculture strain.

J. Philip, M. Dellinger, D. Benhaim

The study examines risk-taking behavior in Arctic charr across group and solitary contexts, finding it repeatable but not correlated between contexts.

bioRxiv · Dec 6, 2021Animal Behavior & Cognition

Cdc6 is sequentially regulated by PP2A-Cdc55, Cdc14 and Sic1 for origin licensing in S. cerevisiae

J. Philip, M. Ord, A. Silva, S. Singh, J. F. X. Diffley, D. Remus, M. Loog, A. E. Ikui

This study identifies the sequential regulation of Cdc6 phosphorylation by PP2A-Cdc55, Cdc14, and Sic1 in S. cerevisiae to control origin licensing.

bioRxiv · Sep 14, 2021Cell Biology

Anti-tumor effects of an Id antagonist with no acquired resistance

P. M. Wojnarowicz, M. G. Escalono, Y.-H. Huang, B. Desai, Y. Chin, R. Shah, S. Xu, O. Ouerfelli, R. K. Soni, J. Philip, D. C. Montrose, J. H. Healey, V. K. Rajasekhar, W. A. Garland, L. Norton, , R. Benezra

This study demonstrates that AGX51, an Id antagonist, effectively inhibits tumor growth in multiple cancer models without inducing acquired resistance.

bioRxiv · Jan 6, 2020 · PreprintCancer Biology

Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia: A report from the TARGET initiative

N. McNeer, J. Philip, H. Geiger, R. Ries, V.-P. Lavallee, M. Walsh, M. Shah, K. Arora, A.-K. Emde, N. Robine, T. A. Alonzo, E. A. Kolb, A. S. Gamis, M. Smith, D. S. Gerhard, , A. Kentsis

The paper identifies genetic mechanisms of primary chemotherapy resistance in pediatric AML through whole-genome and transcriptome sequencing of treatment-failure cases.

bioRxiv · Nov 26, 2018Cancer Biology